Table 1.
Studies reporting PAI-1 antigen levels (ng/mL) and major adverse cardiovascular events and restenosis
| Event | No Event | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | Year | Study Design | Follow-up (months) | Population of interest | N | PAI-1 (IU/mL) | Range | Death | MI | Restenosis | CVA | N | PAI-1 (IU/mL) | Range |
| Sane et al. [50] | 1991 | Cohort | 24 | Fibrinolytics | 24 | 57 | 58 | 24 | n/a | n/a | n/a | 315 | 54 | 53 |
| Cortellaro et al. [51] | 1993 | Case-Control | 24 | Subgroups Combined | 58 | 11.3 | 0.7 | 13 | 17 | n/a | 20 | 87 | 7.3 | 0 5 |
| Brannstrom et al. [52] | 1995 | Cohort | 46 | Anticoagulant | 38 | 21.9 | 15.1 | 38 | n/a | n/a | n/a | 167 | 16.7 | 11.8 |
| Juhan-Vague et al. [53] | 1996 | Cohort | 24 | MI | 106 | 18.2 | 8 2 | 40 | 66 | n/a | n/a | 2700 | 14.8 | 8.9 |
| Nordt et al. [54] | 1998 | Cohort | 12 | Fibrinolytics | 5 | 28.8 | 14.3 | n/a | n/a | 5 | n/a | 26 | 27.1 | 15.4 |
| Alaigh et al. [55] | 1998 | Cohort | 6 | Elective PCI | 28 | 20.75 | 11.06 | n/a | n/a | 28 | n/a | 45 | 24.5 | 13.85 |
| Moss et al. [56] | 1999 | Cohort | 26 | MI | 81 | 25 | 18 | 25 | 56 | n/a | n/a | 964 | 29 | 28 |
| Redondo et al. [57] | 2001 | Cohort | 24 | MI | 37 | 40.725 | 22.28 | 2 | 5 | 30 | n/a | 157 | 42.65 | 21.02 |
| Fornitz et al. [58] | 2001 | Cohort | 6 | Elective PCI | 7 | 82.6 | 26.6 | n/a | n/a | 7 | n/a | 12 | 72.2 | 27 |
| Bogaty et al. [59] | 2001 | Case-Control | 48 | MI | 23 | 23.83 | 19.04 | n/a | 8 | n/a | n/a | 77 | 18.9 | 16.24 |
| Ganti et al. [60] | 2002 | Cohort | n/a | MI | 4 | 80.68 | 16.38 | 4 | n/a | n/a | n/a | 38 | 61 | 21.95 |
| Lip et al. [61] | 2002 | Cohort | 12 | Stroke | 27 | 56.5 | 30.7 | 27 | n/a | n/a | n/a | 59 | 45.9 | 23.3 |
| Inoue et al. [62] | 2003 | Cohort | 6 | MI | 24 | 28 | 4 | n/a | n/a | 24 | n/a | 42 | 29 | 4 |
| Christ et al. [20] | 2005 | Cohort | 6 | Elective PCI | 25 | 14.8 | 0.7 | n/a | n/a | 25 | n/a | 55 | 16.8 | 2.1 |
| Robinson et al. [63] | 2007 | Cohort | 5 to 51 | Coronary Heart Disease | 19 | 36.3 | 17.9 | 2 | 2 | n/a | 2 | 79 | 45.4 | 25.6 |
| Katsaros et al. [24] | 2008 | Cohort | 6 to 8 | Elective PCI | 12 | 11.69 | 8.05 | n/a | n/a | 12 | n/a | 61 | 22.78 | 18.76 |
| Thogersen et al. [64] | 2009 | Case-Control | n/a | Healthy | 50 | 38.27 | 16.79 | n/a | 50 | n/a | n/a | 56 | 29 | 15.75 |
| Akkus et al. [65] | 2009 | Cohort | 12 | Cardiogenic Shock | 33 | 116.5 | 97.26 | 33 | n/a | n/a | n/a | 27 | 71.33 | 54.79 |
| Pineda et al. [66] | 2010 | Cohort | 36 | MI | 25 | 65.13 | 53.3 | 4 | 21 | n/a | n/a | 117 | 70.1 | 48.34 |
| Wennberg et al. [67] | 2012 | Case-Control | 168 | Healthy | 469 | 57.28 | 25.83 | n/a | 469 | n/a | n/a | 895 | 51.23 | 25.11 |
| Yano et al. [68] | 2013 | Cohort | 20 | Smokers | 66 | 65.73 | 64.57 | n/a | 11 | n/a | 55 | 744 | 42.97 | 36.54 |
| Yano et al. [69] | 2014 | Cohort | 30 | Hypertension | 42 | 31.67 | 16.12 | 4 | 13 | n/a | 16 | 548 | 28.33 | 14.87 |
| Knudsen et al. [70] | 2014 | Case-Control | 12 | HIV | 54 | 111 | 8.5 | 3 | 51 | n/a | n/a | 54 | 92 | 7 |
| Golukhova et al. [71] | 2015 | Cohort | 28 | Elective PCI | 23 | 72.75 | 29.86 | 2 | 9 | 11 | n/a | 71 | 49.75 | 23.16 |
CVA cerebrovascular accident